{
    "root": "304db758-37e4-4402-e063-6294a90ad22e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin and Clavulanate Potassium",
    "value": "20250314",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CETYL ALCOHOL",
            "code": "936JST6JCN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_487869"
        }
    ],
    "indications": {
        "text": "amoxicillin clavulanate potassium indicated treatment infections adults pediatric patients , due susceptible isolates designated bacteria conditions listed : lower respiratory tract infections- caused beta\u2011lactamase\u2011producing isolates haemophilus influenzaeand moraxella catarrhalis . acute bacterial otitis media- caused beta\u2011lactamase\u2011producing isolates h. influenzaeand m. catarrhalis . sinusitis- caused beta\u2011lactamase\u2011producing isolates h. influenzaeand m. catarrhalis . skin skin structure infections- caused beta\u2011lactamase\u2011producing isolates staphylococcus aureus , escherichia coli , klebsiellaspecies . urinary tract infections- caused beta\u2011lactamase\u2011producing isolates e. coli , klebsiellaspecies , enterobacterspecies . limitations susceptibility test results show susceptibility amoxicillin , indicating beta-lactamase production , amoxicillin clavulanate potassium used . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin clavulanate potassium antibacterial drugs , amoxicillin clavulanate potassium used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "acute bacterial otitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_206994"
            }
        ]
    },
    "contraindications": {
        "text": "adults pediatric patients greater 40 kg : 500 875 mg every 12 hours 250 500 mg every 8 hours , based amoxicillin component . ( 2.2 , 2.3 ) pediatric patients aged 12 weeks ( 3 months ) older : 25 45 mg/kg/day every 12 hours 20 40 mg/kg/day every 8 hours , adult dose . ( 2.3 ) neonates infants less 12 weeks age : 30 mg/kg/day divided every 12 hours , based amoxicillin component . 125 mg/5 ml oral suspension recommended . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "amoxicillin clavulanate potassium tablets , usp , 875 mg/125 mg : film coated tablet , oral , white , capsule-shaped , scored debossed ggn7 one side scored reverse side , contains 875 mg amoxicillin trihydrate 125 mg clavulanic acid potassium salt . ndc : 70518-3624-00 ndc : 70518-3624-01 ndc : 70518-3624-02 ndc : 70518-3624-03 packaging : 100 1 box packaging : 1 1 pouch packaging : 30 1 blister pack packaging : 14 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium beta-lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium . ( 4.2 )",
    "indications_original": "Amoxicillin and clavulanate potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  \n                     \n                        Lower Respiratory Tract Infections- caused by beta\u2011lactamase\u2011producing isolates of\n  \n   Haemophilus influenzaeand\n  \n   Moraxella catarrhalis.\n \n  \n                     \n                        Acute Bacterial Otitis Media- caused by beta\u2011lactamase\u2011producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n                     \n                     \n                        Sinusitis- caused by beta\u2011lactamase\u2011producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Skin and Skin Structure Infections- caused by beta\u2011lactamase\u2011producing isolates of\n  \n   Staphylococcus aureus, Escherichia coli,and\n  \n   Klebsiellaspecies.\n \n  \n                     \n                        Urinary Tract Infections- caused by beta\u2011lactamase\u2011producing isolates of\n  \n   E. coli,\n  \n   Klebsiellaspecies, and\n  \n   Enterobacterspecies.\n \n  \n                  \n                  \n                     Limitations of Use\n                  \n                  When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium should not be used.\n                  \n                     Usage\n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 )",
    "warningsAndPrecautions_original": "Amoxicillin and Clavulanate Potassium Tablets, USP, 875 mg/125 mg: Each film coated tablet, for oral administration, is white, capsule-shaped, scored and debossed GGN7 on one side and scored on the reverse side, and contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt.\n                  \n                  NDC: 70518-3624-00\n                  NDC: 70518-3624-01\n                  NDC: 70518-3624-02\n                  NDC: 70518-3624-03\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin and clavulanate potassium or to other beta-lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and clavulanate potassium. ( 4.2 )",
    "drug": [
        {
            "name": "Amoxicillin and Clavulanate Potassium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        }
    ]
}